Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient

作     者：Maria Salvado Victor Vargas Marta Vidal Macarena Simon-Talero Jessica Camacho Josep Gamez 

作者机构：ALS UnitNeurology DepartmentHospital Universitari Vall d'HebronVall d'Hebron Research InstituteAutonomous University of Barcelona Liver UnitDepartment of MedicineHospital Universitari Vall d'HebronVall d'Hebron Research InstituteAutonomous University of BarcelonaBarcelona. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD)Instituto de Salud Carlos IIIMadridSpain Pathology DepartmentHospital Universitari Vall d’HebronVall d’HebronAutonomous University of Barcelona 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第36期

页      面：10475-10479页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100204[医学-神经病学] 10[医学] 

基　　金：Supported by Grants from the Spanish Fondo de Investigaciones Sanitarias no.PI13-01272(to Gamez J) an Interlaken Research Awards Program 

主　　题：Drug-induced liver injury Masitinib Amyotrophic la 

摘      要：We report a case of acute severe hepatitis resulting from masitinib in a young amyotrophic lateral sclerosis patient. Hepatotoxicity induced by masitinib,a tyrosine kinase inhibitor,is usually transient with mild elevation of transaminases,although acute hepatitis has been not reported to date. The hepatitis was resolved after masitinib was discontinued and a combination of prednisone and azathioprine was started. The transaminases returned to baseline normal values five months later. This is the first case in the hepatitis literature associated with masitinib. The autoimmune role of this drug-induced liver injury is discussed. Physicians should be aware of this potential complication.